Work

643P Evaluating biomarkers in metastatic castration resistant prostate cancer (mCRPC) patients (Pts) treated with enzalutamide (Enza): PSA, circulating tumor cell (CTC) counts, AR-V7 status, PET imaging vs. CT & Tc99 scans

Year: 2020

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2020.08.902

Authors: S. Gandhy, E.M. Gonzales, F. Karzai, J. Marte, M. Bilusic, S. McMahon, J. Strauss, S. Steinberg, A. Gill, A. Tubbs, J. Schonhoft, P. Choyke, B. Turkbey, L. Lindenberg, W.D. Figg, P. Arlen, W. Dahut, J.L. Gulley, R.A. Madan

Institutions: National Cancer Institute, National Institutes of Health, Center for Cancer Research, Epic Sciences (United States)

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Pfizer, AstraZeneca, Sanofi, Bladder Cancer Advocacy Network, Astellas Pharma

OpenAlex ID: W3087793632

FWCI: 0.123

Cites:

Cited by: 1

Related to: 10